HEOR Consulting Saudi Arabia

SFDA and payer context for Saudi HEOR consulting

Saudi HEOR runs on a single evidence chain, and understanding how its links connect is the first step in scoping any engagement. A budget impact analysis (BIA) sizes the affordability question — what a therapy will cost the payer over the next several years. A cost-effectiveness analysis (CEA) sizes the value question — whether the health outcomes gained justify that cost, expressed as cost per QALY. Both feed into an HTA (health technology assessment) dossier, the structured review SFDA uses to decide registration and pricing. And the same evidence base then carries into market access work — NUPCO tender submissions and MOH or NGHA institutional formulary review — where it has to keep doing commercial work well after the initial registration decision. Sponsors who treat these as four unrelated deliverables routinely duplicate effort or discover a gap mid-review; BioNixus scopes them as one coordinated program from the outset.

SFDA's Economic Evaluation System (EES) — mandatory from 1 July 2025, following the Economic Evaluation Studies Guideline (published July 2024) and Pharmacoeconomic Submission Portal Manual (January 2025) — is the framework this entire evidence chain has to satisfy. EES classifies budget impact analysis and cost-minimisation analysis as "Partial Economic Studies," the lighter evidence tier, and cost-utility analysis (CEA) plus cost-benefit analysis as "Full Economic Studies," the tier expected where a product's clinical and cost profile makes comparative effectiveness against standard of care a material consideration. Which tier a specific product needs is the first question a HEOR program has to answer, since it determines whether a BIA alone is sufficient or a full CEA and HTA dossier is required.

NUPCO's centralized procurement model changes what HEOR evidence has to prove once SFDA registration clears. NUPCO's technical committee evaluates budget impact and value narratives alongside supply-security and volume-commitment criteria that sit outside SFDA's own review — a model built only to satisfy SFDA registration is not automatically the same document a NUPCO tender evaluator wants to see. Regional MOH formulary committees and National Guard Health Affairs (NGHA) layer additional institutional review on top of both, meaning HEOR evidence built for one gate does not automatically clear the next one without deliberate translation.

Local epidemiology, treatment pathways, and pricing assumptions have to be defensible to medical affairs, market access, and finance stakeholders simultaneously — not only health economists — because a HEOR program that satisfies a technical reviewer but cannot be explained by the access team in a committee room has not actually done its job. Cross-functional translation of model outputs into committee-ready language is as important as the underlying spreadsheet architecture, which is why BioNixus builds the assumption base once and frames outputs for each internal audience from that same source, rather than reconciling separate narratives after the fact.

For GCC portfolios, Saudi HEOR modules should harmonize core metrics with UAE and Kuwait appendices without averaging away Kingdom-specific procurement logic — SFDA's EES framework, NUPCO's national tender structure, and the scale of MOH and NGHA institutional buyers are genuinely Kingdom-specific, and a model built to be portable across the GCC by blending them into a regional average ends up satisfying no single market's reviewers.

SFDA reviewers expect transparent limitation statements alongside sensitivity and scenario outputs at every stage of the evidence chain — BIA, CEA, and HTA dossier alike. BioNixus documents input provenance and limitation statements in committee-ready appendices from the start of an engagement, not retrofitted before submission, so the same audit trail that satisfies an SFDA reviewer also satisfies an internal compliance or finance review.

Cross-functional workshops that lock epidemiology, treatment-mix, and pricing inputs before model build begins are what let a HEOR program move from BIA through CEA and into HTA dossier assembly without re-litigating the same assumptions at each stage — a discipline that saves real time across a coordinated Saudi HEOR program, where the alternative is re-deriving inputs separately for each deliverable.

Why local HEOR assumptions win Saudi reimbursement committees

Health economists with direct SFDA Economic Evaluation System submission experience and Arabic-fluent stakeholder engagement capability are a genuinely scarce combination in the Saudi market — thinner than the pool of HEOR specialists serving NICE- or IQWiG-anchored European submissions — which means sponsors who split BIA, CEA, and HTA dossier work across separate vendors often pay a hidden coordination tax: each new team re-learns the product's clinical story and re-derives epidemiology inputs the previous team already validated. Continuity of the same team across all four pillars is less a convenience than a genuine cost and timeline advantage in a market where that expertise does not scale easily.

Sequencing decisions — whether to build the budget impact model before or alongside the cost-effectiveness analysis, and when to bring market access research into the program rather than treating it as a post-registration afterthought — materially change both program cost and how defensible the evidence looks in review, because a BIA built without knowing the CEA's comparator choice, or a CEA built without knowing which NUPCO or MOH gate it ultimately has to clear, routinely needs partial rework once the fuller picture emerges. BioNixus makes the sequencing call explicit at the scoping stage rather than defaulting to whichever pillar the sponsor happened to ask about first.

Saudi Arabia accounts for roughly USD 9.4 billion of the GCC's approximately USD 23.7 billion 2024 pharmaceutical spend, and Vision 2030's Health Sector Transformation Program is the explicit policy rationale behind SFDA's shift toward mandatory economic evaluation — the stated move from volume-based to value-based healthcare financing is why HEOR evidence, not clinical efficacy alone, now gates registration, pricing, and reimbursement decisions across the entire BIA-CEA-HTA-market access chain.

Imported global models that ignore Saudi treatment mix, the dual public–private channel structure, and local pricing fail committee scrutiny — delaying listing even when the underlying clinical evidence is strong. This applies as much to a cost-utility (CEA) model's QALY inputs and ICER framing as it does to a budget impact model's uptake curve: Saudi Arabia has not published a single, officially codified cost-effectiveness threshold, and the most cited research-derived estimate — roughly SAR 50,000 to 75,000 per QALY — is explicitly a research estimate, not government policy, which means the credibility of a model's inputs carries more weight in review than hitting a specific ICER target.

Budget impact model design with Saudi-specific assumptions, cost-effectiveness modeling calibrated to defensible comparator selection, and value communication testing for institutional stakeholders together reduce rework before SFDA and NUPCO milestones. BioNixus builds models and narratives calibrated to the Kingdom, then translates outputs into evidence packages access, medical, and finance teams can defend together — as one coordinated program rather than four separately-scoped deliverables.

Scenario planning across the HEOR evidence chain should include NUPCO rescoring shocks, biosimilar entry, and step-therapy tightening — sensitivity tables that committees expect to see whether the deliverable in front of them is a budget impact model, a cost-effectiveness analysis, or the combined HTA dossier those two feed into.

Explore the healthcare market research hub for regional context and related services.

The four Saudi HEOR pillars BioNixus delivers

Saudi HEOR consulting methodology

BioNixus scopes a Saudi HEOR program around the specific decision gate it needs to clear — SFDA EES registration, a NUPCO tender submission, an MOH regional formulary review, or an NGHA institutional listing — and confirms which tier of economic evidence that gate actually requires before any model work begins. Objective lock to one decision, rather than a generic "HEOR support" brief, is what prevents an unfocused deliverable that a committee cannot act on.

Where a product's profile places it in SFDA's Full Economic Study tier, BioNixus sequences the budget impact analysis and cost-effectiveness analysis as one coordinated build from a shared dataset — epidemiology, treatment-mix, and pricing inputs are documented once, with named owners and defensible sources, rather than re-derived separately for each analysis. This sequencing is what allows the same evidence base to carry from BIA through CEA and into HTA dossier assembly without re-litigating assumptions at each stage.

Assumption workshops bring access, medical affairs, HEOR, and finance stakeholders together to document population, treatment-mix, and pricing inputs before model architecture is finalized, so every assumption that will face committee scrutiny has a named owner who can defend it under questioning.

Model validation includes an internal adversarial review before external delivery — BioNixus stakeholders deliberately challenge comparator choice, input provenance, and sensitivity coverage the way an SFDA or NUPCO reviewer would, across whichever combination of BIA, CEA, and HTA dossier components the engagement covers, so weak points are surfaced while there is still time to strengthen the evidence.

Value narrative testing uses pre-specified objection frameworks so message variants map to institutional reactions, translating whatever combination of budget-impact and cost-effectiveness findings the model produces into language a payer committee, a NUPCO tender evaluator, or an MOH formulary reviewer actually responds to.

Every deliverable — whether a standalone BIA, a combined BIA-plus-CEA package, or a full HTA dossier — ships with an audit-ready assumption log and limitation-statement appendix documenting input provenance in a format SFDA reviewers, NUPCO tender evaluators, and internal compliance teams can review without requiring the original modeling team to reconstruct the logic after delivery.

Typical timeline from objective lock to a first executable draft is one to three weeks for a focused, single-decision scope, depending on which combination of BIA, CEA, and HTA dossier components the engagement covers and how much Saudi-specific data already exists versus needing primary collection.

Cross-functional readouts should include market access, medical affairs, commercial, and—where relevant—finance representatives in one structured session. When each function receives a differently framed deck, affiliates lose weeks reconciling incompatible narratives before committee or launch decisions.

BioNixus documents recruitment sources, exclusion reason codes, and quota telemetry in audit-ready appendices so medical affairs and compliance reviewers can trace sample integrity without requesting ad hoc forensics after field closes.

For multinational sponsors, harmonized variable dictionaries and coding frameworks let regional roll-ups compare Saudi, UAE, Kuwait, and Egypt cells without forcing identical institutional assumptions that would distort local access realism.

Ethics permissions, hospital data-use agreements, and MOH research authorizations can extend timelines when not mapped during feasibility. Early feasibility sprints surface these gates before recruitment calendars lock and budgets commit.

Objection libraries should rank hesitations by decision stage—registration, formulary, tender, or post-listing defence—so medical and access teams know which evidence gap to close first rather than treating all pushback as equivalent.

Value narrative testing uses neutral vignettes and pre-specified reaction coding so message variants map to institutional behaviour without promotional contamination that would fail compliance review.

Sensitivity and scenario tables accompany every economic model so committees see what changes when epidemiology, pricing, or uptake assumptions move—transparency builds credibility faster than point estimates alone.

Common Saudi HEOR consulting use cases

HEOR demand peaks when SFDA submission, NUPCO listing, or formulary defence requires a coordinated budget-impact, cost-effectiveness, and HTA evidence package rather than a single standalone deliverable.

• SFDA EES dossier support across BIA, CEA, and HTA components
• NUPCO budget impact and tender-facing value submissions
• Full HTA dossier assembly for chronic, oncology, and specialty products
• Biosimilar value defence
• Launch sequencing economics
• Price–volume scenario planning
• Medical–access narrative alignment
• GCC roll-up from a Saudi anchor model

Saudi HEOR engagement timeline

1. Step 1

   Objective, decision-gate, and evidence-tier lock

   BioNixus confirms which specific gate the program needs to clear and which combination of BIA, CEA, and HTA dossier components that gate genuinely requires, mapping what Saudi-specific data already exists versus what needs primary collection — typically one week to a scoped proposal.

2. Step 2

   Coordinated model build and QA

   Budget impact and, where required, cost-effectiveness analysis are built from a shared dataset with sensitivity and scenario analysis, followed by an internal adversarial stress-test before external delivery — typically two to three weeks depending on scope.

3. Step 3

   Value narrative and stakeholder testing

   Optional module translating model outputs into committee-ready language, tested against pre-specified objection frameworks for the specific institutional audience — SFDA, NUPCO, MOH, or NGHA.

4. Step 4

   Committee-ready handover and carry-through

   Final deliverables include the model file(s), assumption and limitation log, executive summary, and a 30/60/90 action plan — scoped so the same evidence base can carry from HTA registration into NUPCO tender or institutional formulary review without rebuilding from scratch.

Saudi HEOR program outputs

• Program scoping memo naming which combination of BIA, CEA, HTA, and market access components the engagement covers
• Shared assumption base with named owners, reused consistently across every pillar the program includes
• Sequencing plan showing the order pillars are built in and how each carries into the next
• Internal adversarial stress-test summary applied consistently across whichever pillars are in scope
• 30/60/90 action plan flagging evidence gaps and next steps across the full evidence chain
• GCC harmonization note describing how the Saudi anchor model extends to UAE, Kuwait, or Qatar appendices where relevant
• Audit-ready assumption log with sensitivity tables spanning BIA, CEA, and HTA components
• Committee-ready executive summary and slide narrative for SFDA, NUPCO, MOH, or NGHA audiences
• Optional qual reaction coding aligned to model scenarios

Executive decision blueprint